ANAB vs ESTA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ANAB's Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 2/9, indicating significant distress risk, and no Altman Z-Score available, which raises red flags for solvency. Despite this, the company exhibits extraordinary growth momentum with 151% YoY revenue growth and a stellar 319.4% YoY EPS growth, supported by consistent earnings beat rates and large positive surprises. The stock trades at a premium valuation (Price/Sales: 7.94, Price/Book: 48.80), but this is justified by its high-growth biotech profile and strong analyst consensus. Insider selling activity is bearish, but the magnitude of recent earnings upside and market momentum suggest underlying strength. The overall picture reflects a high-risk, high-reward speculative opportunity.
ESTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ANAB vs ESTA: Head-to-Head Comparison
This page compares AnaptysBio, Inc. (ANAB) and Establishment Labs Holdings Inc. (ESTA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.